Nobuhiko Sawa

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya et al. · Investigational New Drugs · 2019 · 53 citations

Pharmacy, Oncology, Pharmacotherapy +16

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto et al. · Clinical Lung Cancer · 2020 · 45 citations

Life Sciences, Immunology, Oncology +14

Levels of Antibody against Glycopeptidolipid Core as a Marker for Monitoring Treatment Response in Mycobacterium avium Complex Pulmonary Disease: a Prospective Cohort Study

Seigo Kitada, Ryoji Maekura, Kenji Yoshimura et al. · Journal of Clinical Microbiology · 2016 · 25 citations · Full text

Medicine, Immunology, Internal Medicine +14

Pulmonary rehabilitation for COPD improves exercise time rather than exercise tolerance: effects and mechanisms

Keisuke Miki, Ryoji Maekura, Seigo Kitada et al. · International Journal of COPD · 2017 · 19 citations · Full text

Medicine, Rehabilitation Medicine, Exercise Testing +16